kabutan

Nano Holdings, Inc.(4571) Summary

4571
TSE Growth
Nano Holdings, Inc.
139
JPY
0
(0.00%)
Jan 29, 3:10 pm JST
0.91
USD
Jan 29, 1:12 am EST
Result
PTS
outside of trading hours
138.9
Jan 29, 3:12 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.98
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
139 JPY 0.90 USD
Previous Close Jan 28
139 JPY 0.91 USD
High Jan 29, 9:00 am
139 JPY 0.91 USD
Low Jan 29, 9:04 am
136 JPY 0.88 USD
Volume
186,000
Trading Value
0.03B JPY 0.19M USD
VWAP
137.68 JPY 0.9 USD
Minimum Trading Value
13,900 JPY 91 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
89
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
446
1-Year High Oct 10, 2025
15,902
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 6,285,800
Jan 16, 2026 0 5,829,600
Jan 9, 2026 0 5,702,900
Dec 26, 2025 0 5,516,800
Dec 19, 2025 0 5,345,600
Company Profile
NANO MRNA Co., Ltd. is a biotech venture specializing in mRNA therapeutics. The company is expanding its pipeline through collaborations and partnerships, with high expectations for treating intractable cancers.
Sector
Pharmaceuticals
NANO MRNA Co., Ltd. has been developing innovative pharmaceuticals, primarily focusing on anticancer drugs that encapsulate small molecules and other medicines within nanoparticles using micellar nanoparticle technology. In January 2023, the company shifted its business model to concentrate on mRNA therapeutics. mRNA therapeutics involve administering artificially manufactured mRNA to the body, enabling the expression of proteins encoded by the mRNA to prevent or treat diseases. The company is advancing multiple mRNA pipelines, including regenerative medicine for osteoarthritis of the knee, immune tolerance vaccines, and preventive vaccines for infectious diseases. NANO MRNA conducts research and development up to the preclinical trial stage and then licenses out to pharmaceutical companies. The company actively pursues joint research with academia, pharmaceutical, and non-pharmaceutical companies to expand its pipeline of new candidates. In addition to mRNA, NANO MRNA continues to develop brain tumor treatments and siRNA drugs targeting transcription factors. The company aims to establish a development system rivaling major pharmaceutical companies and create innovative medicines.